For moderate to severe rheumatoid arthritis (RA) in adult TNFi-IR patients1

DEFY EXPECTATIONS

Challenge treatment
goals in RA

Exceptional access is already here. RINVOQ has achieved >95% preferred commercial coverage Exceptional access is already here. RINVOQ has achieved >95% preferred commercial coverage Exceptional access is already here. RINVOQ has achieved >95% preferred commercial coverage

RINVOQ met ALL primary (ACR20 or ACR50 at Week 12 or 14) and ranked secondary endpoints across clinical trials, with some achieving ACR20 as early as Week 1 in SELECT-BEYOND.1,3  
See results below

*RINVOQ is on a preferred tier or otherwise has preferred status on the plan’s formulary.
Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

ACR=American College of Rheumatology; IR=intolerance or inadequate response; MTX=methotrexate; TIM=targeted immunomodulator; TNFi=tumor necrosis factor inhibitor

Join an upcoming educational speaker program webinar Join an upcoming educational speaker program webinar Join an upcoming educational speaker program webinar

RINVOQ (upadacitinib) met all primary and ranked secondary endpoints1,4

Primary Endpoint Results
(Week 12 or 14)

Primary Endpoint Results (Week 12/14) Primary Endpoint Results (Week 12/14) Primary Endpoint Results (Week 12/14)

SELECT-BEYOND: 27% RINVOQ 15 mg + csDMARD vs 11% Placebo + csDMARD1,3,†

SELECT‑BEYOND
(Study RA‑V):1,3

12‑week, randomized, double‑blind, placebo‑controlled study of 499 adult patients with moderate to severe RA who had an inadequate response or intolerance to bDMARDs.

SELECT‑EARLY
(Study RA‑I):1,5

48‑week, randomized, double‑blind, active comparator‑controlled study of 947 adult patients with moderate to severe RA who were MTX‑naïve.

SELECT‑
MONOTHERAPY (Study RA‑II):1,6

14‑week, randomized, double‑blind, active comparator‑controlled study of 648 adult patients with moderate to severe RA who had an inadequate response to MTX.

SELECT‑NEXT
(STUDY RA‑III)1,7

12‑week, randomized, double‑blind, placebo‑controlled study of 661 adult patients with moderate to severe RA who had an inadequate response to csDMARDs.

SELECT‑COMPARE
(Study RA‑IV):1,8

48‑week, randomized, double‑blind, active comparator‑controlled study of 1629 adult patients with moderate to severe RA who had an inadequate response to MTX.

RINVOQ is a once-daily JAK inhibitor1

Durable remission, even without MTX3,6,9,10

Remission* & LDA rates with or without MTX at weeks 12 or 14 with response rates from 60 to 84 weeks in SELECT-BEYOND and SELECT-MONOTHERAPY, respectively

*Does not mean drug-free remission or complete absence of disease activity

Safety data from 21 clinical trials across 6 indications 1,11,*

>11,300 patients in global clinical trials across US-approved indications, including pediatrics 12+ years in AD11,*
>31,200 patient-years of exposure to RINVOQ 15, 30 or 45 mg11,*
>6.5 years max. exposure in RA (~4 yrs median) to RINVOQ 15 mg as of 8/15/2211,†

AbbVie's commitment to exceptional access and patient support

>95% preferred national commercial and Medicare Part D formulary coverage under the pharmacy benefit as of January 20232,‡,§
1:1 support to help RA patients start and stay on track with their prescribed treatment plan

*Includes 3 phase 2 trials and 6 phase 3 RA trials, 2 phase 3 PsA trials, 1 phase 2/3 and 1 phase 3 AS trial, 1 phase 3 nr-axSpA trial, 1 phase 2 and 3 phase 3 AD trials, and 3 phase 3 UC trials. RA: RINVOQ 1  mg, upadacitinib 30 mg; PsA: RINVOQ 15 mg, upadacitinib 30 mg; AS: RINVOQ 15 mg; nr‑axSpA: RINVOQ 15 mg; AD: RINVOQ 15 mg and 30 mg; UC: RINVOQ 15 mg, 30 mg, and 45 mg. RINVOQ 15 mg is the approved dose in RA, PsA, AS, and nr‑axSpA; RINVOQ 15 mg and 30 mg are the approved doses in AD; RINVOQ 15 mg, 30 mg and 45 mg are the approved doses in UC.1,11
In PsA: ~5.0 years maximum exposure (~2.9 years median) to RINVOQ 15 mg as of 08/2022. In AS: ~3.8 years maximum exposure (~1.7 years median) to RINVOQ 15 mg as of 08/2022. In nr‑axSpA: ~2.4 years maximum exposure (~1.0 years median) to RINVOQ 1  mg as of 08/2022.11
RINVOQ is on a preferred tier or otherwise has preferred status on the plan's formulary.
§Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

ACR=American College of Rheumatology; AD=atopic dermatitis; CRP=C-reactive protein; DAS28-CRP=28 joint disease activity score using C-reactive protein; IR=intolerance or inadequate response; max.=maximum; MTX=methotrexate; nr-axSpA=non-radiographic axial spondyloarthritis; TNFi=tumor necrosis factor inhibitor; UC=ulcerative colitis

RINVOQ® COMPLETE

See how UPADAC Complete provides an exceptional access
and patient support experience